iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance.

iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone.  

iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. 

iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.

For more information, please visit www.ionctura.com


FONGIT Innovation Fund

KWF Kankerbestrijding

Health Holland

European Innovation Council

M Ventures

VI Partners

Schroder Adveq

3B Future Health Fund

Inkef

iOnctura

A company focused on developing therapeutic PI3K inhibitors for cancer and immune-dysregulation.

PI3K Inhibitors Company

A company specializing in pharmacological targeting of mitochondrial ion channels to eliminate cancer cells.

Mitochondrial Ion Channel Targeting Company

Ionctura is a clinical-stage biotech company focused on the development of novel anti-cancer ion channel inhibitors. The company leverages its expertise in ion channel pharmacology to target difficult-to-treat cancers with a focus on solid tumors.

Ionctura

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jun 22, 2024 5:38 PM	0599bf3c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jun 22, 2024 8:40 PM	0f704f35
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	27ef6f4c
crunchbase profile	general
li profile	general	Jun 22, 2024 5:38 PM	51fe4370
translate crunchbase fundingrounds	general
peers	general
news basic	general	Jun 22, 2024 5:38 PM	1b79c48d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:IONCTURA

Ionctura